Primary Prevention of Cervical Cancer: HPV Vaccines in India and Pakistan


The majority of cervical cancer diagnoses and deaths occur in countries with limited health resources ~ 22% of the global total of new diagnoses each year occur in Indian women alone. Primary cancer prevention through vaccination has the potential to save lives and prevent both negative health and economic impacts. However, national decision-makers must first possess sufficient awareness of the burden of disease and the value of vaccination before they are willing to implement new, sometimes costly programs. 


With Gavi support, IVAC and Jhpiego will collaborate to support decision-making in selected countries who have a significant cervical cancer disease burden yet have not yet introduced HPV vaccines into their national immunization programs. IVAC’s expertise in vaccine decision-making, introduction, economics, policy, implementation, and evaluation will complement Jhpiego’s expertise in reproductive health program design, implementation, evaluation, and scale-up. IVAC and Jhpiego will synthesize and translate the evidence on investments in HPV vaccines. The team will also work with national and sub-national decision-makers in the selected countries.

The learning agenda extends beyond decision-making and application of existing research to implementation research questions such as how to deliver vaccines to girls who may not be in school or may not be able to go to a health facility, where most girls will have access to vaccines, and how best to integrate HPV vaccines with other adolescent, youth and reproductive and development health services.


This project will:

1) Assess the current landscape in India around readiness to accept new population-wide cervical cancer prevention programming; 2) Help governmental partners develop and disseminate an evidence-based set of scenarios and data syntheses, to understand the trade-offs involved in an investment in HPV vaccination